CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Biovica has developed a highly sensitive assay to measure thymidine kinase levels in serum, which indicates cancer cell proliferation. This technology aims to improve patient-specific treatment predictions and optimize clinical trial cohort selection, making it less invasive and more scalable than existing methods.
Many cancer therapies fail due to inadequate prediction of patient-specific treatment responses.
In addition, a large number of clinical trials fail due to a lack of predictive tools for optimal cohort selection.
Biovica has developed a sensitive and precise assay for the measurement of a biomarker thymidine kinase (TK) from serum as an indicator of cell proliferation.
Our assay technology has been clinically tested and has demonstrated beyond state-of-the-art capability compared to existing sol…
BIOVICA INTERNATIONAL AB
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
